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Malaria causes about 300 million infections annually.1 Approximately 90% of the deaths occur in Africa, with falciparum
malaria a major contributor. For decades, malaria chemotherapy has relied on a limited number of drugs. Acquisition and
spread of resistance to these drugs is largely responsible for a
recent increase in malaria-related mortality (2, 3). This increasing burden caused by drug-resistant parasites has led
investigators to seek out novel antimalarial drug targets.
Among these are enzymes necessary for cellular division and
differentiation. Previous work has demonstrated that the en-
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zyme protein farnesyltransferase (PFT)2 is a viable drug target
for pathogenic protozoa, including the malaria parasite Plasmodium falciparum (4 – 8).3 PFT inhibitors (PFTIs) have been
developed by the pharmaceutical industry because of their
anti-cancer properties (9 –11). Utilizing this existing resource,
we have been able to demonstrate that low nanomolar concentrations of tetrahydroquinoline (THQ)-based PFTIs inhibit
P. falciparum PFT (PfPFT) and are cytotoxic to parasites both
in vitro and in vivo.3
PFT in eukaryotic cells catalyzes the transfer of a 15-carbon
isoprenoid lipid unit, a farnesyl group, from farnesyl pyrophosphate (FPP) to the C terminus of a specific set of proteins,
including the Ras superfamily G-proteins (12). In addition to
the Ras superfamily proteins, which are involved in the cell
cycle, another protein that has been shown to be farnesylated is
CENP-E, a centromere-associating protein, which plays a critical role in cell cycle progression during the M-phase (13).
However, the identification of farnesylated proteins in P. falciparum and their role in mediating PFTI toxicity are currently
under investigation.
Because of the enzymatic nature of the drug target, we have
begun to investigate potential P. falciparum resistance to
PFTIs. The THQ PFTI used in this work, BMS-388891 (Fig. 1),
is a potent inhibitor of parasite proliferation and causes severe
defects in maturation.3 In addition, when parasites were
treated with BMS-388891 and the farnesylated proteins were
labeled with [3H]farnesol, there was a significant decrease in
labeled 37–75-kDa proteins.3
Using a P. falciparum clone prone to the acquisition of drug
resistance (14), we describe the selection of P. falciparum parasites resistant to BMS-388891 and present genetic and enzymological analyses of these parasites. We analyze the native
PFT enzyme of the parent and resistant clones and demonstrate that an amino acid substitution is responsible for PFTI
resistance. In addition, using the solved crystal structure of the
mammalian protein farnesyltransferase, we created a model
for the P. falciparum PFT enzyme that explains the THQ-PFT
binding interactions and explains the molecular mechanism of
resistance (15–18) to better facilitate drug development. Our
work demonstrates PFT as the target for THQ PFTIs and
provides a tool for further characterization of the PFT enzyme
2
The abbreviations used are: PFT, protein farnesyltransferase; THQ,
tetrahydroquinoline; PFTI, protein farnesyltransferase inhibitor;
PfPFT, P. falciparum PFT; FPP, farnesyl pyrophosphate; WT, wild type.
3
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The post-translational farnesylation of proteins
serves to anchor a subset of intracellular proteins to
membranes in eukaryotic organisms and also promotes
protein-protein interactions. Inhibition of protein farnesyltransferase (PFT) is lethal to the pathogenic protozoa Plasmodium falciparum. Parasites were isolated
that were resistant to BMS-388891, a tetrahydroquinoline (THQ) PFT inhibitor. Resistance was associated
with a 12-fold decrease in drug susceptibility. Genotypic
analysis revealed a single point mutation in the ␤ subunit in resistant parasites. The resultant tyrosine 837 to
cysteine alteration in the ␤ subunit corresponded to the
binding site for the THQ and peptide substrate. Biochemical analysis of Y837C-PFT demonstrated a 13-fold
increase in BMS-388891 concentration necessary for inhibiting 50% of the enzyme activity. These data are consistent with PFT as the target of BMS-388891 in P. falciparum and suggest that PFT inhibitors should be
combined with other antimalarial agents for effective
therapy.

PFT Inhibitor-resistant P. falciparum
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TABLE I
Primers used for sequencing PfPFT ␣ and ␤ subunit genes
Using the P. falciparum 3D7 protein farnesyltransferase ␣ and ␤ genomic sequences as a template, primers to amplify and sequence the
P. falciparum Dd2 PFT ␣ and ␤ genes were constructed. The location of the primer relative to the start is given in parentheses.
Primer

Sequence

AACCCATGGAAAATCGATGCTTG
ATCTATATTGAGGAGGGG
TATAATAATTCATTGTGGG

PFT ␣ subunit antisense primers
PfPFT (595)
PfPFT (1120)
PfPFT (End)

TATTATCTATATTTTTCCCC
GTATAAAATATCTATATACCC
GCCCAACATAAAATATCATATTG

PFT ␤ subunit sense primers
PfPFT (Start)
PfPFT (455)
PfPFT (1030)
PfPFT (1522)
PfPFT (2110)
PfPFT (2640)

GATATGAGGAGTTTTAACCATGGAAAAAAATGATTCGTATTTATTG
CAAGTAGATTGTTCACATG
GAAACGGAAGAATATAACG
CACATTGCAACGACTTATG
AAGAGAATGAAATAAAGG
CTATATAATATCACAGTTG

PFT ␤ subunit antisense primers
PfPFT (550)
PfPFT (1000)
PfPFT (1570)
PfPFT (2160)
PfPFT (End)

ATATTTTTCACATATATCTTC
TCAAAAGTATGTAAAGGTG
AAAAGTTATTTTCTTCATCAT
AGTTTATATCCTTTTCACTAC
CCAGATCTTTTTATTTCATTCTTGTAGTAACC

in an effort to develop this as a target of antimalarial
chemotherapy.
EXPERIMENTAL PROCEDURES

Parasites—Experiments described in this study were performed with
a clone of P. falciparum Dd2 strain parasites, which is derived from
clone W2 (14). Parasites were cultured in an asynchronous manner in
vitro using standard conditions and media (19). Parasites from infected
erythrocytes were isolated for PFT enzyme extraction by treatment
with 0.1% (w/v) saponin.
Selection of BMS-388891-resistant Parasites—Selection of resistant
parasites was conducted as described previously (14, 20). Briefly, triplicate 30-ml cultures with a 2% hematocrit and 108 infected red blood
cells of an isogenic, recently cloned population of P. falciparum Dd2
(WT) were challenged with varying concentrations of THQ BMS-388891
(300, 100, 33.3, 11.1, and 3.7 nM) in the culture medium. In addition,
triplicate flasks were inoculated with 10 parasites as a growth control
to gauge when limiting numbers of parasites would appear by microscopy. The medium was changed every other day, maintaining the initial
drug concentration, and fresh red blood cells were added once per week.
Cultures were maintained under continuous drug pressure for 80 days.
Giemsa-stained blood smears of cultures were used to detect parasite
outgrowth, and a 2% infected red blood cell level was considered positive. Clonal isolates of resistant parasites from drug-challenged cultures were generated by limiting dilutions.
Proliferation Assays, ED50—In vitro responses to the THQ PFTI were
calculated from 72-h [3H]hypoxanthine incorporation assays as described previously (21, 22). Incorporation of [3H]hypoxanthine into nucleic acids was measured using a Chameleon liquid scintillation counter
(Hidex, Turku, Finland). The ability of the PFTI to reduce the parasite
growth was reported as an ED50 value, the effective dose of PFTI that
reduces the hypoxanthine incorporation by 50%, compared with the
untreated positive control after subtraction of a no parasite background
control.
Genetic Analysis—Genomic DNA was isolated from the parasites
using standard phenol/chloroform protocols. Duplicate independent
PCR reactions for both the PFT ␣ and ␤ subunits were amplified using
the Expand high fidelity polymerase PCR System (Roche Applied Science). These amplicons were ligated into the pGEMT cloning vector
(Promega, Madison, WI), and five Escherichia coli transformants derived from each PCR reaction were sequenced. Sequencing results were
analyzed using Vector NTI Suite 9.0 (Invitrogen). Primers used to
amplify and sequence the PFT subunits in P. falciparum Dd2 are given
in Table I.
Protein Farnesyltransferase Assay and Determination of IC50—
PfPFT was partially purified from the isolated parasites by ammonium

sulfate fractionation and Q-Sepharose chromatography from parasite
lysates as described by Chakrabarti et al. (5, 23). Peak fractions were
concentrated using a Vivaspin 15R concentrator according to the manufacturer’s recommendations (Vivascience, Hannover, Germany). Assays for PfPFT activity were performed with a PFT-specific scintillation
proximity assay kit (Amersham Biosciences) slightly modified from the
one described previously (23).3 One M biotinylated lamin B peptide
substrate (biotin-YRASNRSCAIM) was used. The concentration of
[3H]farnesyl pyrophosphate (FPP) (3.7 MBq) was increased beyond the
manufacturer’s recommendations to 1 M to ensure that the enzyme
substrate was in excess of its likely Km value (the Km of farnesyl
diphosphate for human PFT is 9.3 ⫾ 5.8 nM) (24). Increasing the FPP
concentration to 2 M had no effect on the amount of the product formed
(data not shown). All reactions were performed in triplicate. Controls
(no enzyme reaction values) were subtracted from experimental values
before calculation of percent inhibition. The effectiveness of the PFTI is
reported as an IC50 value, the concentration of inhibitor that reduces
the activity of the enzyme by 50% compared with the untreated positive
control.
Determination of Km for the Peptide Substrate—Determination of the
Km value for the peptide substrate of the PFT enzyme was conducted
using the scintillation proximity assay as described above. The FPP
substrate concentration was 1 M, whereas the peptide substrate concentrations used were 0, 0.25, 0.5, 1, 2, 3, 4, and 5 M. Each experiment
was repeated in duplicate for both the WT and mutant enzymes. Control values obtained from reactions with no peptide substrate were
subtracted from the experimental values. The experimental values
were graphed as velocity as determined by counts per min obtained as
a function of peptide substrate concentration. These values were fitted
to a Michaelis-Menten plot using Prism 3.0 (Graphpad, San Diego, CA).
Determination of the Ki Values for BMS-388891—Ki values of BMS388891 for both the WT and mutant native PFT enzyme were obtained
by non-linear regression fit of percent inhibition versus inhibitor concentration at fixed peptide substrate concentration (1 M). The Km
values for the WT and Y837C enzyme were used to obtain the value of
Ki for the PFTI by fitting the observed rate data from the IC50 experiments as a function of inhibitor concentration at constant peptide
substrate concentration by non-linear regression. In Equation 1, Vi/V0
is the ratio of enzyme activity in the presence of inhibitor over the
activity without inhibitor, S is the peptide substrate concentration, Km
is the value determined for each enzyme (see Table II), and I is the
concentration of BMS-388891.
V i/V0 ⫽ ([S] ⫹ Km)/([S] ⫹ Km(1 ⫹ [I]/Ki))

(Eq. 1)

Homology Modeling of PfPFT—The program MODELLER (25), version 6v2, was used for the creation of the homology model of PfPFT. The
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PFT ␣ subunit sense primers
PfPFT (Start)
PfPFT (560)
PfPFT (1090)
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FIG. 1. The structures of the tetrahydrobenzodiazepine BMS214662 and of the THQ BMS-388891. The binding mode of BMS214662 to rat PFT has been revealed in a recent x-ray structure (17).
BMS-388891 is the PfPFT inhibitor discussed here. The nomenclature
of the substituents of the THQ used throughout the text is indicated.

RESULTS

BMS-388891-resistant P. falciparum Clones Can Be Selected—Earlier studies demonstrated that P. falciparum 3D7
was highly sensitive to growth inhibition by the THQ PFTI,
BMS-388891, with an ED50 of 7.0 nM.3 To determine whether
resistance to BMS-388891 could occur, a one-step selection
protocol was used employing varying concentrations of BMS388891. We employed a recently cloned Dd2 strain, which is
prone to the acquisition of drug resistance (14). In cultures
treated with 100 nM BMS-388891, two of three flasks developed
parasite growth by day 21. Flasks with inhibitor concentrations

of 33.3, 11.1, or 3.7 nM and the no drug 10 parasite control
flasks all had demonstrable parasites by day 11. In contrast,
after 80 days of continuous culturing the remaining flask
challenged with 100 nM BMS-388891 and all of the flasks
challenged with 300 nM BMS-388891 remained negative for
parasites. Clonal parasites were derived from the populations
of the two 100-nM flasks in which parasite outgrowth occurred,
and these clones were used for further experimentation.
Growth rate of the drug-resistant clones with or without drug
pressure did not differ significantly from the WT population
without drug pressure (data not shown).
BMS-388891-resistant Clones Show 12-Fold Resistance—Resistant clones obtained from the two 100-nM BMS-388891treated flasks showed altered ED50 values compared with the
WT clone, which had an ED50 of 10 nM. Clonal isolates obtained
from the drug selection had an ED50 value of 105 nM (clone
B10), 110 nM (clone G7), and 120 nM (clone H7), a 12-fold
increase in resistance to the inhibitor (Fig. 2). ED50 experiments were conducted multiple times (WT, n ⫽ 5; G7, n ⫽ 4;
H7, n ⫽ 7; B10, n ⫽ 3). Student’s t test demonstrated significance between the ED50 values of the WT and each resistant
clone (p ⬍ 0.01). These clonal isolates retained identical ED50
values after 6 weeks of culture without drug pressure (data not
shown). Thus the BMS-388891 resistance phenotype in these
clones is stable in the absence of drug pressure.
A Single Amino Acid Substitution Causes the Resistance
Phenotype—To identify the basis of resistance, both the ␣ and
␤ genes of PFT from all three resistant clones and the WT clone
were sequenced. Only a single nucleotide difference in the ␤
PFT gene was found between the parent and the resistant
clones, resistant clones being 100% identical. Multiple E. coli
transformants from independent PCRs were used for sequencing to rule out PCR-induced errors. The single point mutation
was a transition from an adenine to a guanine in the ␤ gene.
This mutation altered the predicted amino acid coding of the ␤
subunit at position 837 from a tyrosine to a cysteine. Fig. 3
shows a fragment of the predicted amino acid alignment of the
PFT ␤ subunit from P. falciparum Dd2 WT, P. falciparum Dd2
Y837C mutant clone (all three clones have identical nucleotide
sequence), and the human sequence (NCBI accession number
P49356). Of note, by sequencing the cDNA we can infer the
presence of an intron near the 3⬘-end of the PFT ␣ (data not
shown, GenBankTM accession number AY880030). This intron
is not currently noted in either the NCBI or PlasmoDB
database.
Mutant PfPFT Has a Decreased Affinity for BMS-388891 and
Has an Increased Affinity for Peptide Substrate—The IC50
value for PFT enzyme extracted from the P. falciparum Dd2
WT clone was 0.7 nM. This is similar to the value that was
found previously for P. falciparum 3D7 (0.6 nM).3 However, the
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crystal structure of rat PFT complexed with the non-substrate tetrapeptide inhibitor CVFM and FPP was used as the template structure
(Protein Data Bank file 1JCR (18)). The sequences of the two subunits
of PfPFT were obtained from the PlasmoDB data base (www.plasmodb.
org, Gene loci: PFL2050w for ␣ and chr11.glm_528 for ␤). A BLAST
search resulted in 14 ␣- and 12 ␤-subunit sequences. They were aligned
with the program T-COFFEE (26). The pairwise sequence alignment
used for the homology modeling was extracted from this multiple alignment. Only regions with reasonable reliability of the alignment were
included. The model of PfPFT comprises the following sequence segments (throughout the text corresponding residue numbers of rat PFT
are given in parentheses; these also correspond to the residue numbers
of human PFT): ␣: 72–164 (Rat␣87–179), 300 – 411 (Rat␣184 –283); ␤:
421– 677 (Rat␤71–315), 806 – 896 (Rat␤330 – 417). The levels of sequence identity (similarity) between PfPFT and rat PFT in these regions amount to 23% (53%) for the ␣-subunit and 37% (56%) for the
␤-subunit. The catalytic zinc ion, six structurally conserved water molecules (Protein Data Bank water residue numbers in 1JCR: 1163, 1167,
1170, 1241, 1573, 1181), and FPP were included in the model. The
conformation of FPP was considered to be flexible during the model
calculations. For this purpose parameters for FPP were added to the
MODELLER force field using the lipid parameters of the “charmm27”
force field (27). 20 different models of PfPFT were calculated. The model
with the lowest value of the objective function of MODELLER was used
for further work. The model of the mutant Tyr-␤837 to Cys was obtained by replacing tyrosine with cysteine and selecting the lowest
energy rotamer with INSIGHTII (version 97.0; Accelrys Inc.).
Ligand Docking Calculations—The program FLO (version 6.02) (28)
was used for the docking of BMS-388891, which contains a sulfonamide
functional group (Fig. 1). Most sulfonamide nitrogens show significant
deviations from planarity, i.e. they are pyramidalized (29). The NM
atom type of FLO takes this into account but does not allow for the
inversion of the sulfonamide nitrogen during Monte Carlo conformational searches. To consider the inversion, both stereochemical configurations of this nitrogen were considered in separate calculations.
Thus, to account for both configurations of the chiral carbon atom and
of the sulfonamide nitrogen, four docking calculations were necessary.
The initial placements of the four stereochemical configurations of
BMS-388891 were obtained by modifying the structure of BMS-214662,
a tetrahydrobenzodiazepine (Fig. 1), as observed in the x-ray structure
with rat PFT (17) after superpositioning this structure on the PfPFT
homology model. 2000 cycles of Metropolis Monte Carlo conformational
searches were performed for each starting configuration of BMS-388891
in the PfPFT binding site employing the MCDOCK module of the FLO
program. A distance restraint was introduced for the bond between the
imidazole nitrogen and the zinc ion.

FIG. 2. Growth inhibition by BMS-388891 of P. falciparum WT
and resistant clones G7, H7, and B10. Shown is an in vitro growth
inhibition assay, using [3H]hypoxanthine uptake as a measure of proliferation. Results are shown as percent growth inhibition as a function
of BMS-388891 inhibition concentration. P. falciparum Dd2 WT (Œ),
P. falciparum Dd2 Y837C clones G7 (⽧), H7 (●), and B10 (䡺). Shown
are the mean of multiple replicates and standard deviation.

PFT Inhibitor-resistant P. falciparum
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TABLE II
Difference in affinity of the Y837C mutant PFT enzyme for peptide
substrate and BMS-388891
FIG. 3. Predicted location of the altered residue in the mutant
PFT ␤ subunit. A partial amino acid alignment comparing the predicted sequences of P. falciparum Dd2 wild type, P. falciparum Dd2
Y837C mutant, and the human PFT ␤ subunits.

Clonea

Km

P. falciparum Dd2 WT
P. falciparum Dd2 Y837C

0.64 ⫾ 0.12
0.32 ⫾ 0.1

M

Kib
nM

0.22 ⫾ 0.01
1.2 ⫾ 0.2

a
The YRASNRSCAIM peptide substrate Km values for both the
P. falciparum Dd2 WT and Y837C mutant enzyme isolated from clone
H7 as determined using the Michaelis-Menten plot of activity as a
function of peptide substrate concentration.
b
The Ki values of WT and Y837C mutant P. falciparum PFT enzyme
were determined by fitting the IC50 data as a function of inhibitor
concentration at constant peptide substrate concentration [1 M] by
non-linear regression. All results are given as the mean ⫾ S.D. of three
experimental replicates.

mutant PFT enzyme extracted from resistant clone H7 had an
IC50 value against BMS-388891 of 9 nM, 13-fold higher than the
WT enzyme (Fig. 4). This is almost identical to the 12-fold shift
seen in the ED50 value comparing WT and resistant isolates.
This correlation implicates the alteration of the PFT enzyme as
the cause for the observed drug resistance of the parasite and
thus demonstrates that the mechanism of action of the THQ
class of PFT inhibitors is by direct interaction and inhibition of
the PFT enzyme. IC50 experiments for both the WT enzyme and
the Y837C mutant enzyme were conducted three times with a
Student’s t test demonstrating p ⬍ 0.01, a statistically significant difference.
The Km values of both WT and the Y837C mutant PFT
enzyme for the peptide substrate YRASNRSCAIM is listed in
Table II. The values from the calculation of BMS-388891 Ki
values for both WT and the Y837C enzyme are shown in Table
II. The mutated enzyme has a higher affinity for the peptide
substrate (lower Km) and also reduced the binding affinity of
BMS-388891 (higher Ki). Together these alterations allow the
mutant PFT enzyme to function in the presence of higher
concentrations of PFTI compared with the WT PFT enzyme.
Of note, this class of PFTIs has displayed little to no selectivity for the P. falciparum PFT enzyme compared with the
mammalian PFT enzyme (data not shown). This lack of selectivity is supported by the homology model (see below).
Homology Model of PfPFT—The homology model of PfPFT
reveals that despite the relatively low overall level of sequence
identity (see under “Experimental Procedures”), many of the
residues contacting BMS-214662 in mammalian PFT are conserved (17). Five conservative substitutions of the surface residues in proximity of the inhibitor are obvious. Residues in rat
PFT with a side chain atom within 7Å from BMS-214662 that
are replaced in PfPFT (RatPFT3PfPFT) are: Tyr-␤93 3 Leu␤443 (3.6 Å), Cys-␤95 3 Ser-␤445 (4.5 Å), Tyr-␣166 3 Phe␣151 (4.8 Å), Phe-␤360 3 Tyr-␤836 (5.5 Å), Ala-␣129 3 Ser␣114 (6.1 Å) (Fig. 5). The conformation of the FPP molecule,
which contributes to the surface contacting BMS-214662, was
left unchanged by MODELLER.
Docking of BMS-388891—The best predicted binding mode
of BMS-388891 to wild-type PfPFT was obtained for the (S)enantiomer. It shows high similarity to the binding mode of
BMS-214662 (Fig. 5); the root mean square deviation of the

DISCUSSION

Here we report the first instance of parasites with resistance
to PFTIs. These parasites have increased resistance to PFTIs,
specifically BMS-388891, a THQ. The only observed amino acid
substitution was Y837C in the ␤ subunit of PFT. This mutation
affects both the enzyme affinity for the peptide substrate and
the THQ inhibitor, which likely contribute to the drug-resistant phenotype. These resistant clones, obtained from two independently cultured flasks, are identical to the WT parent
clone except for the Y837C mutation.
Experimental results using the PFT enzyme purified from
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FIG. 4. BMS-388891 inhibition of PFT enzyme from the parent
clone and resistant clone H7. Using the native PFT enzyme isolated
from both P. falciparum Dd2 WT (Œ) and Y837C mutant clone H7 (●),
the percent enzyme inhibition as a function of BMS-388891 inhibitor
concentration was determined. Shown are the mean values and standard deviation of multiple experiments.

cyano-phenyl group and the adjacent carbon and nitrogen atoms of the saturated ring and of the zinc-binding R3 groups
(Fig. 1) amounts to 1.2 Å. The BMS-388891 R2 fills the pocket
occupied by the benzyl substituent of BMS-214662. The pocket
is partly formed by the side chain of Tyr-␤837[Rat␤361], but
only one of the two terminal carbon atoms of R2 is contacting
this side chain. Both sulfonamide oxygen atoms are solvent
accessible. One of them is located at a distance of 3.5 Å from the
NH2 side chain nitrogen atom of Arg-␤564[Rat␤202], suggesting that minor changes of the position of this side chain might
allow for the formation of a hydrogen bond. In fact, minimization of the ligand in the docked orientation considering the side
chain conformation of Arg-␤564[Rat␤202] as flexible, lead to
formation of this hydrogen bond (N–O distance: 3.0 Å). The
arginine side chain shows a slight shift toward the sulfonamide
group upon the minimization, whereas the ligand position remains unchanged. The imidazole attached to the SO2 group (R1
in Fig. 1) is contacting the phenyl ring of Phe-␣151[RatTyr␣166] in an edge to face orientation. The 16 best predicted
ligand binding positions show a highly conserved placement of
R2, whereas the position of R1 shows variability. However, in
most cases the edge to face orientation of R1 with the Phe-␣151
phenyl ring is maintained. The best predicted binding energy
for the WT enzyme is ⫺21.1 kJ/mol. (Note that the association
energy contributed by the binding of the imidazole nitrogen
atom to the zinc ion is not considered by the docking program.)
The BMS-388891 binding mode predicted for the Y837C mutant of PfPFT shows a nearly identical position of the ring
system and the zinc binding moiety as well as highly similar
locations of the sulfonamide substituents (Fig. 5). The change
of the shape of the R2 pocket by the mutation leads to a shift of
R2 toward the side chain of the newly introduced cysteine. The
position of the terminal carbon of the R2 group that is contacting the Tyr-␤837 side chain in the wild type changes by about
2.4 Å. The score for the best predicted binding mode in the
mutant binding site is ⫺15.4 kJ/mol, which is 5.7 kJ/mol higher
than the wild-type enzyme. This apparent increase in binding
energy would be expected with the increased Ki for the inhibitor as observed experimentally.
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the WT clone and a resistant clone revealed that the Km value
for the peptide substrate in the Y837C mutated enzyme is
decreased by half. In addition, the Y837C mutated enzyme
demonstrates reduced binding affinity for BMS-388891, as
demonstrated by a 6-fold increase in the Ki value of BMS388891 for the Y837C versus the WT enzyme. The combination
of the 2-fold increase in affinity for the peptide substrate and
the 6-fold decreased affinity for BMS-388891 likely contributes
to the 13-fold increase in the IC50 of the Y837C mutant enzyme.
Mutagenesis studies of the yeast and human PFT enzyme
have provided clues to the impact of altering residues which
have proximity to the catalytic zinc ion (30 –32). Del Villar et al.
(32) demonstrated that alteration of the homologous residue in
the human PFT enzyme, Tyr-␤361 (corresponding to PfPFT
␤837) to Leu, plays a critical role in peptide substrate binding
and resistance to tricyclic inhibitors (Schering-Plough PFT inhibitors SCH44342 and SCH56582). In addition, the Del Villar
study (32) demonstrates that this alteration alters the affinity
for peptide substrates. Our finding that the Km was decreased
in the Y837C mutant relative to the WT PfPFT is consistent
with this residue being in proximity to the binding site of the
peptide substrate in PfPFT.
Findings with the PFT mutants are supported by determination of the three-dimensional crystal structure of the mammalian PFT enzyme (15, 16, 18). Specifically, the crystal structure of the mammalian PFT bound to BMS-214662, a
tetrahydrobenzodiazepine PFTI related to the THQ series,
demonstrates the striking interaction between the aromatic
ring structure of the PFTI and the aromatic ring of RatTyr␤361 (17).
The good agreement of the predicted binding mode of BMS388891 with the binding geometry of BMS-214662 reflects the
structural similarity of these inhibitors and the high degree of
conservation of the binding site region relevant for the binding
of BMS-214662. The difference in binding energy of BMS388891 with the mutation Y837C amounts to 4.3 kJ/mol (calculated with ⌬G ⫽ ⫺ RT ln Ki, with the Ki of the WT enzyme
being 0.22 nM and that of the Y837C enzyme 1.2 nM; see Table
II). This is in good agreement with the predicted binding energy difference of 5.7 kJ/mol.
According to the scoring function of FLO, the mutation leads
to a lower energy conformation of the THQ PFTI in the binding
site; the ligand strain for BMS-388891 drops from 9.2 to 2.2
kJ/mol. However, this only partly compensates a loss of favorable van der Waals interactions. The van der Waals energy

(computed as the sum of the van der Waals and the contact
energy terms of the FLO force field) of the mutant complex is
11.4 kJ/mol higher than that of the wild-type complex. This can
mainly be ascribed to the superior fit of the planar tyrosine side
chain against the bicyclic ring system of the inhibitor. In the
x-ray structure with BMS-214662 the cyano-phenyl group of
the inhibitor is found in a favorable parallel-displaced orientation with respect to the aromatic ring of RatTyr-␤361 (17). The
predicted binding mode of BMS-388891 to PfPFT shows the
cyano-phenyl group in a highly similar position relative to
the homologous residue Tyr-␤837 (Fig. 5). The association free
energy of benzene in aqueous solution has been reported to be
⫺6.3 kJ/mol (33). This value is close to the binding free energy
difference of BMS-388891 between the WT PfPFT enzyme and
the Y837C mutant. This suggests that, in agreement with what
was indicated by the different contributions to the FLO score,
the loss of the favorable interaction between the cyano-phenyl
and the aromatic ring of the Tyr side chain is the major reason
for the observed effect of the Tyr replacement by Cys. Thus, the
effect of this mutation on the binding energy of other THQs,
given that they adopt the same binding mode, is expected to be
highly similar.
One might argue that the mutation Y837C could affect the
geometry and/or the electronic properties of the zinc system
leading to impaired binding of BMS-388891 solely because of
less favorable interaction of R3 with the zinc ion. As in the
mammalian enzyme, the phenyl ring of the Tyr-␤837 side
chain, RatTyr-␤361, is in van der Waals contact with the zinccoordinating His-␤838[Rat␤362] and Cys-␤661[Rat␤299]. Further, the oxygen atom of the Tyr-␤837 side chain is located at a
distance of only 3.2 Å from the sulfur atom of Cys-␤661 suggesting the presence of a hydrogen bond. However, the replacement of the homologous residue, Tyr-␤361, by Leu in the mammalian PFT does not appreciably affect the affinity for the
tetrapeptide substrates CIIM, CIIC, and CIIA (32). Thus, a
potential hydrogen bond to the sulfur atom of the zinc binding
cysteine does not appear to have an appreciable effect on the
ligand binding properties of the zinc ion. The finding that no
significant change of the geometry of the zinc system is observed in the recent related structure of GGTase I, where a Leu
replaces the Tyr corresponding to Tyr-␤837[Rat␤361] (34), further supports the assumption that the mutation Y837C does
also not affect the geometry of the zinc system.
Our finding that a single amino acid substitution can shift
the sensitivity of PfPFT by 13-fold demonstrates the liability of
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FIG. 5. Predicted binding mode of BMS-388891 to the PfPFT enzyme. Left, superposition of the best predicted binding mode for
BMS-388891 (yellow carbon atoms) with BMS-214662 (light blue carbons) as bound to rat PFT. Residues that contribute to the contact surface of
the inhibitors or that are within 7 Å from BMS-214662 and that are not conserved between rat and PfPFT (see Homology Model of PfPFT under
“Results”) are specified. Right, superposition of the binding modes of BMS-388891 as predicted for WT PfPFT (yellow carbon atoms) and the Y837C
mutant (gray carbon atoms). The side chain of Cys-␤837 is shown in green. From this perspective the slightly changed location of R2 in the mutant
enzyme is evident. (Figure prepared with PyMol (DeLano Scientific, San Carlos, CA).)

PFT Inhibitor-resistant P. falciparum
enzyme inhibitors for malaria therapy. It is estimated that an
infected individual with a 2% parasitemia harbors ⬃1011 parasites (1). We have demonstrated that the Y837C mutation can
arise independently at least twice in 3 ⫻ 108 parasites. This
suggests that this mutation could arise multiple times in each
infected individual. This, however, does not negate the potential use of this or other enzyme inhibitors as chemotherapeutic
agents for malaria. It is likely that THQ PFTIs, as well as other
antimalarials, will need to be combined with other agents to
achieve cures and to decrease the occurrence of drug resistance.
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